Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral vancomycin therapy in pediatric PSC-UC and treatment-resistant atypical ulcerative colitis
ACTRN12624001372572Phase 3Not yet recruiting
- Sponsor
- Queensland Children's Hospital
- Start
- Jan 2025
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of vancomycin in autoimmune colitis (3 arms), sponsored by Queensland Children's Hospital. Primary endpoints: Faecal calprotectin remission, Change in colonoscopy Mayo score and 1 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
vancomycin
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ACTRN12624001372572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001372572.